Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Tiziana Pharma
Tiziana Pharma
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
Tiziana announces positive PET scan results with intranasal Foralumab in patients with na-SPMS
Five out of six patients in FDA authorised expanded access programme are showing a qualitative reduction in microglia activation (a key biomarker being observed)
Manufacturing
Tiziana Life Sciences appoints Chief Development Officer
William A. Clementi will take up the role of Chief Development Officer, which will become effective as of September 1 2023
Research & Development
Tiziana develops novel treatment for COVID-19 patients using anti-interleukin-6-receptor mAbs
Company has filed patent application in support of treatment of COVID-19 utilizing anti-il6r via inhaled delivery
Research & Development
Tiziana strengthens unique research focus by appointing Dr Kunwar Shailubhai CEO
Pharmaceutical
Tiziana Life Sciences appoints Arun Sanyal to its Scientific Advisory Board
Arun Sanyal is a professor and a key opinion leader in liver diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Ingredients
Tiziana Life Sciences in-licenses NI-1201, a fully human anti-IL-6R monoclonal antibody
Exclusive worldwide license expands therapeutic pipeline in key immunological areas
Research & Development
Tiziana acquires bio-repository from Shardna and establishes Sardinian subsidiary LonGevia
Aims to further enhance and develop its portfolio using data from the biobank and genomics research
Subscribe now